That might give Breo a boost when approved in Asthma. It seems GSK finally realized - shocking really - they actually need a plan for newly approved respiratory drugs, get out of yesteryear's strategy of more convenient regimen worth of premium pricing by pushing/giving incentive to switch to newer drugs.
Market Data 
Markets 
AI
